Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 10/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | BRD1 | O95696 | 4/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 4/20 | 0.42 |
| ▸ | BRPF3 | Q9ULD4 | 4/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117509 | 0.87 | ACLY (0.42) | ACLYSTAT3BRD1BRPF1BRPF3 | |
| SCHEMBL3467342 | 0.84 | ACLY (0.45) | ACLYSTAT3BRD1BRPF1BRPF3 | |
| SCHEMBL3467341 | 0.82 | ACLY (0.43) | ACLYALPLHSD11B1 | |
| SCHEMBL2119329 | 0.81 | GHSR (0.45) | ACLYSMN1; SMN2 | |
| SCHEMBL2117333 | 0.77 | ALDH1A1 (0.54) | ACLYHSD11B1SMN1; SMN2 | |
| SCHEMBL2119623 | 0.77 | GHSR (0.45) | — | |
| SCHEMBL2117577 | 0.76 | MAPT (0.45) | SMN1; SMN2 | |
| SCHEMBL3467338 | 0.75 | CTSA (0.38) | ACLYALPLSMN1; SMN2 | |
| SCHEMBL2119339 | 0.74 | ACLY (0.48) | ACLYSTAT3BRD1BRPF1BRPF3 | |
| SCHEMBL2118272 | 0.73 | MEN1 (0.44) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | ACLY 1578/4885STAT3 99/4885BRD1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.